The Future Of Medicine: Cell And Gene Therapies Take The Lead
Risk-taking required, partnerships essential to advance the field
BIO panel with Roche’s James Sabry, Spark’s Federico Mingozzi and Adaptive’s Harlan Robins imagines a world where cell and gene therapies are preferred over small molecules and antibodies.
You may also be interested in...
Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharma industry.
Dyno raised $9m in 2018 but came out of stealth mode with deals worth up to $2bn based on its platform using high throughput biology, AI and machine learning to engineer next-generation AAV capsids.